We are live on ! Find out more
GLG Partners

GLG Partners Portfolio holdings

AUM $2.14B Turnover 59.22%
1-Year Est. Return 21.14%
This Fund
S&P 500
This Quarter Est. Return
+5.42%
1 Year Est. Return
+21.14%
3 Year Est. Return
+49.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
+$251M
Cap. Flow
-$130M
Cap. Flow %
-6.09%
Top 10 Hldgs %
20.07%
Holding
564
New
243
Increased
78
Reduced
76
Closed
91
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 27.22%
2 Consumer Discretionary 13.47%
3 Technology 9.7%
4 Financials 9.51%
5 Industrials 8.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
DGX icon
326
Quest Diagnostics
DGX
$28.7B
$162K 0.01%
+1,645
New +$156K
2017 Q4
0 quarters
DHR icon
327
Danaher
DHR
$163B
$159K 0.01%
+1,933
New +$157K
2017 Q4
0 quarters
CTSO icon
328
Cytosorbents
CTSO
$15.2M
$156K 0.01%
+1,202
New +$153K
2017 Q4
0 quarters
CSRA icon
329
DELISTED
CSRA
CSRA
$154K 0.01%
5,160
– –
2017 Q2
2 quarters
HP icon
330
Helmerich & Payne
HP
$3.77B
$153K 0.01%
+2,360
New +$132K
2017 Q4
0 quarters
ALNY icon
331
Alnylam Pharmaceuticals
ALNY
$21.6B
$152K 0.01%
+1,200
New +$151K
2017 Q4
0 quarters
PSEC icon
332
Prospect Capital
PSEC
$802M
$152K 0.01%
+22,600
New +$147K
2017 Q4
0 quarters
TYME
333
DELISTED
Tyme Technologies
TYME
$152K 0.01%
+23,820
New +$106K
2017 Q4
0 quarters
ADM icon
334
Archer Daniels Midland
ADM
$34.2B
$151K 0.01%
+3,775
New +$155K
2017 Q4
0 quarters
AIG icon
335
AIG
AIG
$43.1B
$150K 0.01%
+2,524
New +$155K
2017 Q4
0 quarters
O icon
336
Realty Income
O
$56.3B
$150K 0.01%
+2,713
New +$147K
2017 Q4
0 quarters
HII icon
337
Huntington Ingalls Industries
HII
$12B
$141K 0.01%
600
-900
-60% -$212K
2017 Q1
3 quarters
COST icon
338
Costco
COST
$491B
$140K 0.01%
+752
New +$130K
2017 Q4
0 quarters
FTNT icon
339
Fortinet
FTNT
$91.5B
$131K 0.01%
15,000
-4,430
-23% -$36.1K
2017 Q2
2 quarters
SAIC icon
340
SAIC
SAIC
$6.32B
$130K 0.01%
1,700
-366
-18% -$26.5K
2017 Q2
2 quarters
CLVS
341
DELISTED
Clovis Oncology
CLVS
$128K 0.01%
1,886
-347
-16% -$24.3K
2017 Q3
1 quarter
ARWR icon
342
Arrowhead Research
ARWR
$6.59B
$118K 0.01%
+31,974
New +$119K
2017 Q4
0 quarters
ACAD icon
343
Acadia Pharmaceuticals
ACAD
$3.24B
$114K 0.01%
+3,794
New +$121K
2017 Q4
0 quarters
BAH icon
344
Booz Allen Hamilton
BAH
$10.4B
$114K 0.01%
3,000
-3,000
-50% -$113K
2017 Q1
3 quarters
XRAY icon
345
Dentsply Sirona
XRAY
$1.81B
$114K 0.01%
+1,737
New +$110K
2017 Q4
0 quarters
TFC icon
346
Truist Financial
TFC
$59.8B
$113K 0.01%
+2,269
New +$110K
2017 Q4
0 quarters
GLW icon
347
Corning
GLW
$92.6B
$109K 0.01%
3,400
+347
+11% +$10.9K
2017 Q2
2 quarters
USB icon
348
US Bancorp
USB
$94.6B
$107K 0.01%
+2,004
New +$108K
2017 Q4
0 quarters
EXC icon
349
Exelon
EXC
$48.2B
$106K 0.01%
+3,767
New +$108K
2017 Q4
0 quarters
MRK icon
350
Merck
MRK
$366B
$105K ﹤0.01%
+1,952
New +$108K
2017 Q4
0 quarters

Similar funds

GLG Partners's Q4 2017 Portfolio in Review

As of Q4 2017, GLG Partners held 564 positions worth $2.14B, up 13% from $1.89B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

GLG Partners withdrew a net $130M in Q4 2017, closing 91 positions and reducing 76 holdings. Its most notable exit was Sciclone Pharmaceuticals, an estimated $29M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, GLG Partners opened a new position in Advanced Accelerator Applications S.A. worth $49.2M.

  • GLG Partners's largest Q4 2017 buy was Advanced Accelerator Applications S.A.: 603,055 shares worth $49.2M.
  • GLG Partners added most to NXP Semiconductors in Q4 2017, an estimated $35M increase.
  • GLG Partners's biggest Q4 2017 reduction was Criteo, cutting an estimated $22.5M.
  • GLG Partners fully exited Sciclone Pharmaceuticals in Q4 2017, selling an estimated $29M.
  • GLG Partners's ten largest holdings make up 20% of its $2.14B portfolio in Q4 2017.
  • GLG Partners opened 243 new positions and closed 91 in Q4 2017.
  • GLG Partners's portfolio value rose 13% quarter-over-quarter to $2.14B.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.